Thu, Aug 13, 2020
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

The Corona Fighters Report 55: Asset managers who delivered in the downturn

Monday, July 13, 2020

amb
Bailey McCann, Opalesque New York:

This is our regular report on hedge funds and alternative asset managers who are successfully protecting assets and outperforming the markets during the first months of 2020.

Biomedical companies continue to outperform

Vista Point Capital's flagship biotech fund - Parallax Biomedical Fund was up 2% (est.) in June and is up 11.7% year to date through June 30th. The fund was also up in Q1 2020 and ended 2019 up 54.20% following strong activity in the sector.

Biomedical companies have outperformed in recent months as the demand for covid-related solutions heats up alongside a growing demand for biomedical services overall. Biomedical companies like Moderna, for example, are working on a potential vaccine for Covid-19. The US government's Operation Warp Speed, which provides funding to fastrack the development of a coronavirus vaccine, provided a significant capital injection to a group of biomedical companies that could begin work on a coronavirus vaccine immediately. Most of that funding went to large-cap biomedical companies, but small-cap biomedical companies with products in the pipeline often become targets for acquisition by large-cap companies in this sector.

Parallax makes investments in small-cap biotechnology and medical technology companies. The investment team is typically looking for companies that have later stage products in development or those that have low valuations with room to grow. The strategy takes advantage of the high barriers to entry for biomedical companies. The field is complex and inefficient which lead to dislocations in the stocks that can be beneficial for opportunistic traders. The fund runs a concentrated portfolio of 20-25 core positions and invests in both US and European companies.

Vista Point is led by Marc Pentopolous. Pentopolous founded Katana Pharmaceuticals and has decades of experience in medical technology, drug development, and finance. He also led Emerging Growth Management's medical technology strategy.

Marc Pentopolous will be a presenter in our fourth Corona Fighters webinar discussing the biomedical sector and other portfolio diversifiers. Registration is free.

View prior reports: Report 54

Webinar: The Corona Fighters Episode 4

Meet five more asset managers who delivered during the meltdown.

Time: Tuesday, July 21st, 10 am EST
Details and registration: www.opalesque.com/webinar/


New eBook: The Corona Fighters COLLECTION - A Handbook for Investors

200+ funds that were up or protected assets in Q1 2020: A Compendium of Opalesque Corona Fighters Report #1 to Report #52

Download here: www.opalesque.com/ebook.

***

Disclaimer: This is not investment advice. Opalesque has not verified this information and gives no warranty of accuracy or completeness. Past performance is not indicative of future results. See our Terms & Conditions for more information.

***


WEBINARS:

Meet 15 fund managers and learn how and why their strategies delivered positive returns and/or protected capital during the Corona led market meltdown! Each webinar lasts an hour and features five managers.

"The whole Corona Fighters program has been extremely educational for me and a great opportunity to learn more about hedge funds and compare/contrast their approaches." (Single Family Office Principal)

Video replays of Opalesque's past webinars can be found here: www.opalesque.com/webinar/#pastwebinar

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. GCM Grosvenor to merge with Cantor Fitzgerald SPAC, to go public[more]

    Laxman Pai, Opalesque Asia: GCM Grosvenor, a global alternative asset management solutions provider with approximately $57 billion in assets under management, is planning to go public by merging with a special purpose acquisition company backed by the financial-services firm Cantor Fitzgerald in

  2. Ocean Avenue Capital Partners wraps up the fourth fund at $350m[more]

    Laxman Pai, Opalesque Asia: California-based lower-middle market private equity firm Ocean Avenue Capital Partners (OACP) has closed its fourth fund at a hard cap of $350 million, beating its $300 million target. OACP, which manages approximately $1.3 billion of capital, expects that represe

  3. New Launches: Hedge-fund launches pick up despite Covid-19 pandemic, Taconic launches new credit fund, Deerfield raises another $2.5bn as investors flock to health care investments, Blackstone's second fund targeting GP stakes raises $3.5bn so far, Morgan Stanley IM targets greener recovery with Euro sustainable funds, UCL hits $131m first close for sophomore venture capital fund, Fulcrum launches climate change fund, Blackbird raises $356m fund, Crypto venture fund raises $110m from universities, Prime Capital launches Liquid Alternatives Credit fund of funds[more]

    Hedge-fund launches pick up despite Covid-19 pandemic From WSJ: Raising money for a new hedge fund long was contingent on a host of in-person meetings. But a slate of managers are launching sizable startup funds despite complications wrought by the new coronavirus. Hedge-fund man

  4. PE/VC: How private equity co-investments can accelerate investor returns following a crisis, Pandemic slowed private equity fund closings in first half, Private-equity giants inking more deals in Asia[more]

    How private equity co-investments can accelerate investor returns following a crisis Investing in a post-crisis period is never simple. The atmosphere of opportunity compels investors to put capital to work. However, where and how to best invest becomes more important than ever. P

  5. Investing: Viking Global slashes exposure to hot tech stocks, Warren Buffett may have bought back a record $7bn of Berkshire Hathaway stock in the past 3 months[more]

    Viking Global slashes exposure to hot tech stocks From Institutional Investor: Viking Global Investors in the second quarter sharply cut back on positions in at least three of the market's hottest tech and internet stocks, according to a regulatory filing made public late Friday afterno